-
December 2019
Sigmapharm relaunches its generic Griseofulvin Tablets, USP (microsize) 500 mg, exclusively under its own label.
-
October 2019
Sigmapharm files an Abbreviated New Drug Application (ANDA No. 213896) which is designated by the FDA as a Competitive Generics Therapy (CGT) product.
-
June 2019
Sigmapharm launches its generic Ambrisentan Tablets, 5mg and 10mg.
-
May 2019
Dr. Spireas, the Founder, Chairman and Chief Executive Officer of Sigmapharm Laboratories, received today (May 14, 2019) an Honorary Doctor of Science (D.Sc.) degree from Long Island University, Brooklyn, New York.
-
April 2019
Sigmapharm receives FDA approval for generic Ambrisentan Tablets, 5 mg and 10 mg, based on its ANDA No. 208354 containing a Paragraph IV certification.
